Uploaded July 2026 | Updated November 2026, 3 days ago
The LIFTMOR trial put 101 postmenopausal women with low bone density, average age 65, many told for years to avoid this, on heavy deadlifts, squats, and presses. Their bone density went up, compliance was 92%, and the only injury in the entire study was one back spasm. We explain the mechanism (bone is living tissue that remodels to the magnitude, rate, and novelty of strain, which is why walking and Pilates do not do it), then take on the other reason heavy lifting got avoided in this group: the pelvic floor. A 2024 crossover study found heavy squats and deadlifts did not worsen pelvic floor function versus rest, leaking is common whether women lift or not, and the move for symptoms is pelvic floor physical therapy, not quitting the thing that protects your bones.
0:00 The LIFTMOR trial
1:30 The results: bone density went up
1:57 Reading the trial honestly (the caveats)
3:13 Why walking won't build bone
4:18 Talking to the osteoporosis patient
8:03 Does heavy lifting wreck the pelvic floor?
9:32 Leaking: what actually helps
10:40 The bedridden-angina analogy
13:16 It's never too late to start
Resources:
Menopause Series Part 1 : youtube.com/watch?v=yzk0IkTy0WM
Menopause Series Part 2 — youtube.com/watch?v=YKAlamIOiwU
Menopause Series Part 3 — youtube.com/watch?v=jzoNMQaBAcI
Hypercortisolism episode - open.spotify.com/episode/7tDdUi8dDFWjMYx0fRJdOz
Barbell Medicine coaching and templates: barbellmedicine.com
Signal book pre-order: barbellmedicine.com/shop/learning/signal
Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res. 2018;33(2):211-220. doi.org/10.1002/jbmr.3284
Lambert C, Beck BR, Harding AT, Watson SL, Weeks BK. A comparison of bone-targeted exercise with and without antiresorptive bone medication: the MEDEX-OP randomized controlled trial. J Bone Miner Res. 2021. doi.org/10.1002/jbmr.4334
Bone-targeted high-intensity training does not reduce quality of life related to pelvic floor dysfunction: the MEDEX-OP randomized controlled trial. Int Urogynecol J. 2025. doi.org/10.1007/s00192-025-06187-x
Skaug KL, Engh ME, Bø K. Acute effect of heavy weightlifting on the pelvic floor muscles in strength-trained women: an experimental crossover study. Med Sci Sports Exerc. 2024;56(1):37-43.
Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10:CD005654. doi.org/10.1002/14651858.CD005654.pub4
Skaug KL, Engh ME, Bø K. Pelvic floor muscle training in female functional fitness exercisers: an assessor-blinded randomised controlled trial. Br J Sports Med. 2024;58(9):486-493. pubmed.ncbi.nlm.nih.gov/38413133
The LIFTMOR trial put 101 postmenopausal women with low bone density, average age 65, many told for years to avoid this, on heavy deadlifts, squats, and presses. Their bone density went up, compliance was 92%, and the only injury in the entire study was one back spasm. We explain the mechanism (bone is living tissue that remodels to the magnitude, rate, and novelty of strain, which is why walking and Pilates do not do it), then take on the other reason heavy lifting got avoided in this group: the pelvic floor. A 2024 crossover study found heavy squats and deadlifts did not worsen pelvic floor function versus rest, leaking is common whether women lift or not, and the move for symptoms is pelvic floor physical therapy, not quitting the thing that protects your bones.
0:00 The LIFTMOR trial
1:30 The results: bone density went up
1:57 Reading the trial honestly (the caveats)
3:13 Why walking won't build bone
4:18 Talking to the osteoporosis patient
8:03 Does heavy lifting wreck the pelvic floor?
9:32 Leaking: what actually helps
10:40 The bedridden-angina analogy
13:16 It's never too late to start
Resources:
Menopause Series Part 1 : youtube.com/watch?v=yzk0IkTy0WM
Menopause Series Part 2 — youtube.com/watch?v=YKAlamIOiwU
Menopause Series Part 3 — youtube.com/watch?v=jzoNMQaBAcI
Hypercortisolism episode - open.spotify.com/episode/7tDdUi8dDFWjMYx0fRJdOz
Barbell Medicine coaching and templates: barbellmedicine.com
Signal book pre-order: barbellmedicine.com/shop/learning/signal
Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res. 2018;33(2):211-220. doi.org/10.1002/jbmr.3284
Lambert C, Beck BR, Harding AT, Watson SL, Weeks BK. A comparison of bone-targeted exercise with and without antiresorptive bone medication: the MEDEX-OP randomized controlled trial. J Bone Miner Res. 2021. doi.org/10.1002/jbmr.4334
Bone-targeted high-intensity training does not reduce quality of life related to pelvic floor dysfunction: the MEDEX-OP randomized controlled trial. Int Urogynecol J. 2025. doi.org/10.1007/s00192-025-06187-x
Skaug KL, Engh ME, Bø K. Acute effect of heavy weightlifting on the pelvic floor muscles in strength-trained women: an experimental crossover study. Med Sci Sports Exerc. 2024;56(1):37-43.
Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10:CD005654. doi.org/10.1002/14651858.CD005654.pub4
Skaug KL, Engh ME, Bø K. Pelvic floor muscle training in female functional fitness exercisers: an assessor-blinded randomised controlled trial. Br J Sports Med. 2024;58(9):486-493. pubmed.ncbi.nlm.nih.gov/38413133




![The FDA Voted for 6 Peptides. Its Own Scientists Said No
An FDA advisory committee just voted to open a legal compounding supply line for six of seven peptides, including BPC-157 and TB-500, over the objection of the FDAs own scientists, who recommended against all seven. Dr. Jordan Feigenbaum walks through what the Pharmacy Compounding Advisory Committee actually voted on, why a vote about ulcerative colitis ends up governing tendon and joint use, what the single human BPC-157 trial does and doesnt show, and why a pharmacy makes it safe and theres no money to study it dont hold up. Evidence-based, no hype, no nocebo.
Timestamps:
| 00:00:00 | The FDA voted 8-6. What it actually means
| 00:01:25 | What I am, and am not, claiming
| 00:03:21 | How they got here: Category 2 and the paperwork
| 00:07:17 | Who was in the room: the panel that flipped
| 00:10:57 | What they voted on: compounding and the bulks list
| 00:15:37 | No money in it, you cant patent it
| 00:18:24 | The trials already run: Plevna and MK-677
| 00:22:55 | I took it and it worked: placebo and fake surgery
| 00:27:02 | The one human trial: Ruenzi 2005
| 00:32:28 | Is it natural? Is it even a drug?
| 00:36:58 | Harm reduction, or follow the money?
| 00:42:45 | Three times a missing trial went wrong
| 00:50:58 | Safety: known, unknown, and unknowable
| 00:55:22 | The other six peptides
| 00:58:22 | What Id actually tell you
| 01:02:08 | What actually works, and what would change my mind
Resources:
• Barbell Medicine coaching and templates: https://www.barbellmedicine.com
• Plus podcast subscription: https://www.barbellmedicine.com/shop/subscriptions/plus-podcast-subscription/
• Barbell Medicine Premium: https://www.barbellmedicine.com/shop/subscriptions/barbell-medicine-premium/
• Signal (book pre-order): https://www.barbellmedicine.com/shop/learning/signal/
1. US Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting. July 23-24, 2026. Silver Spring, MD: FDA; 2026.
2. US Food and Drug Administration. FDA review of BPC-157-related bulk drug substances. PCAC Briefing Document. July 23-24, 2026. Media 193343. Accessed July 24, 2026. https://www.fda.gov/media/193343/download
3. US Food and Drug Administration. FDA review of TB-500-related bulk drug substances. PCAC Briefing Document. July 23-24, 2026. Media 193349.
4. US Food and Drug Administration. FDA review of KPV-, MOTS-c-, Semax-, Epitalon-, and Emideltide-related bulk drug substances. PCAC Briefing Documents. July 23-24, 2026.
5. US Food and Drug Administration. Questions for the Pharmacy Compounding Advisory Committee. July 23-24, 2026.
6. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting roster. July 23-24, 2026. Media 193772.
7. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting roster. 2022. Media 159040.
8. openFDA. FAERS adverse event reports for BPC-157. Accessed July 24, 2026. https://open.fda.gov
9. Pharmacy compounding; 503A bulk drug substances. 21 CFR §216.23 (2026).
10. Federal Food, Drug, and Cosmetic Act §503A, 21 USC §353a (pharmacy compounding).
11. Abigail Alliance for Better Access to Developmental Drugs v von Eschenbach, 495 F3d 695 (DC Cir 2007).
12. United States v Rutherford, 442 US 544 (1979).
13. Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, Pub L No. 115-176, 132 Stat 1372 (2018).
14. US Food and Drug Administration. Regulatory considerations for human drug products containing peptides. Guidance for Industry (draft). 2020.
15. Ruenzi M, Stolte M, Veljaca M, et al. Efficacy and safety of PL 14736 (BPC 157) in patients with active ulcerative colitis [abstract]. Gastroenterology. 2005. Meeting abstract; full study not published.
16. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-1117. doi:10.1002/jor.20089
17. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
18. Sikiric P, Skrtic A, Gojkovic S, et al. Stable gastric pentadecapeptide BPC 157 and hemorrhage/thrombosis. Pharmaceuticals (Basel). 2026;19(3):463. doi:10.3390/ph19030463
19. Stavchansky VV, Filippenkov IB, Dergunova LV, Limborska SA. The role of glyprolines in the regulation of gene expression: focus on Semax. Genes (Basel). 2022;13(12):2380. doi:10.3390/genes13122380
20. Mendias CL, Awan TM. The safety and efficacy of approved and unapproved peptides. Sports Med. 2026. doi:10.1007/s40279-026-02437-0
21. Moseley JB, OMalley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347(2):81-88. doi:10.1056/NEJMoa013259
22. Cobb LA... The FDA Voted for 6 Peptides. Its Own Scientists Said No](https://i.ytimg.com/vi/KwPlmH8HORg/mqdefault.jpg)





